Skip to content

The risk of different maternal feeding patterns in patients who had High HBVDNA load and received antiviral treatment during pregnancy

The risk of different maternal feeding patterns in patients who had High HBVDNA load and received antiviral treatment during pregnancy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025539
Enrollment
Unknown
Registered
2019-08-31
Start date
2019-08-29
Completion date
Unknown
Last updated
2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mother-to-child blocking of hepatitis B

Interventions

1:Breast feeding
2:Artificial feeding

Sponsors

Beijing YouAn Hospital Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: In the chronic hepatitis b prevention guide "diagnostic criteria of chronic hepatitis b virus infection, HBV - DNA or 1 x 106 iu/ml immune tolerance for pregnant women, the house at 24 to 28 weeks began to block for than, or for the purpose of oral tenofovir maternal and infant, gestational age 37w - 42w, baby weight 2500 g, or observation group continued breastfeeding (including mixed feeding) 3 to 6 months. Ensure that the subjects voluntarily choose to participate in this study and are eligible for follow-up.

Exclusion criteria

Exclusion criteria: Pregnant women with hepatitis b immune tolerance but without intrauterine blockade, chronic hepatitis b patients who received anti-viral treatment before pregnancy, hepatitis activists during pregnancy, severe gestational complications and complications, such as gestational heart disease, severe preeclampsia, poor blood glucose control of gestational diabetes mellitus, premature delivery, FGR, etc. People with severe medical complications are not suitable for breastfeeding.

Design outcomes

Primary

MeasureTime frame
HBV-M;

Countries

China

Contacts

Public ContactRuihua Tian

Beijing YouAn Hospital Capital Medical University

1572805079@qq.com+86 13661060631

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026